Roger Sawhney's most recent trade in Actuate Therapeutics Inc. was a trade of 15,000 Stock Options done . Disclosure was reported to the exchange on May 22, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Actuate Therapeutics Inc. | Roger Sawhney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 15,000 | 15,000 | - | - | Stock Options | |
| Actuate Therapeutics Inc. | Roger Sawhney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2024 | 30,000 | 30,000 | - | - | Non-Qualified Stock Options | |
| Alimera Sciences Inc. | Roger Sawhney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2023 | 2,252 | 2,252 | - | - | Stock Option (Right to Buy) | |
| Omega Therapeutics Inc | Roger Sawhney | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2022 | 60,000 | 60,000 | - | - | Option (Right to Buy) | |
| Omega Therapeutics Inc | Roger Sawhney | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 17.00 per share. | 03 Aug 2021 | 2,941 | 2,941 | - | 17 | 49,997 | Common Stock |